Metrics as of 10/15/2026, 02:19 PM (Berlin time), refresh in progress.
Pulmonx Stock
Pulmonx Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Glendon E. French
- Employees
- 296
- Market cap
- $76 M
- IPO
- 01/10/2020
- Web
- pulmonx.com
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted…
Pulmonx stock: price history
1D
-3.8%
1W
-3.3%
1M
-8.7%
6M
+21.1%
YTD
-19.5%
1Y
+13.4%
2Y
-73.8%
5Y
-95.5%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~168% stronger price swings than usual
Ask the agents about Pulmonx
Analyst assessment of Pulmonx
PRICE TARGET LOW
US$2.50
CONSENSUS
US$10.00
MEDIAN
US$9.75
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
4
BUY
4
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 30/04/2026
Pulmonx stock metrics
P/E
-1.55
P/B
1.92
EV/EBITDA
-1.79
RETURN ON EQUITY
-25.7%
NET MARGIN
-44.3%
DEBT/EQUITY
1.43
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.6%
FLOAT SHARES
37,608,940
AVG. DAILY VOLUME (30D)
279,197
Insider transactions (SEC)
Rose Geoffrey Beran
Rose Geoffrey Beran
Lehman David Aaron
Lehman David Aaron
Lehman David Aaron
Institutional holders
Comparable stocks
Frequently asked questions about Pulmonx stock
What does Pulmonx do?
Pulmonx Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Glendon E. French, the company employs around 296 people.
The IPO was on 01/10/2020; the stock trades on NASDAQ under the ticker LUNG.
What do analysts say about Pulmonx stock?
9 analysts rate the stock, the consensus is Buy (as of 30/04/2026).
The average price target is US$10.00, ranging from US$2.50 to US$20.00, with a median of US$9.75.
This is an external assessment, not a statement by Market Jury.
When does Pulmonx report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 168% stronger than usual.
Does Pulmonx pay a dividend?
No, Pulmonx currently does not pay a dividend.
Which stocks are comparable to Pulmonx?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Pulmonx stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pulmonx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.